400MD, Research Associate III / II, Genomics

Job Code 400MD


Fate Therapeutics is currently seeking a talented and highly motivated Research Associate with a background in nucleic acid purification and next generation sequencing (NGS) library processing to join a multidisciplinary team dedicated to the discovery and characterization of novel induced pluripotent stem cell (iPSC)-derived cellular therapeutics. The candidate will play a key role in Fate’s Genomics group, executing NGS-based assays in support of Fate’s efforts to generate and characterize best-in-class iPSC-derived cellular therapies. The ideal candidate will be highly collaborative and communicative and have extensive hands-on experience in extracting and purifying DNA and RNA from cells and tissues for use in NGS. This position will require adherence to tight deadlines, strong independent and collaborative research abilities, a high level of organization, and the ability to communicate effectively across multidisciplinary teams. This is a full-time, bench-level position reporting to a Scientist in the Genomics group and is located at the Company’s corporate headquarters in San Diego, California.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 400MD.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.